Nitric Acid Skin Lesion Composition with Copper-Zinc Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compositions for treating skin diseases using nitric acid are unstable and lose effectiveness over time, leading to reduced stability and increased risk of side effects, particularly ulcerations on healthy skin, due to variations in nitrite concentration.
Innovation Solution
A pharmaceutical composition comprising a therapeutic quantity of nitric acid, copper salt, lactic acid, oxalic acid, acetic acid, and zinc salt, which maintains stable nitrite concentration through differential oxidation rates and synergistic action of copper and zinc, promoting cellular immunity and healing while minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nitric acid is used to treat skin diseases, then therapeutic effectiveness is achieved, but stability over time deteriorates due to nitrite concentration variations
Solution Approach 1:
The patent changes the chemical composition parameters by introducing copper salts and organic acids (lactic, oxalic, acetic acid) to nitric acid solutions. This creates a complex chemical system where copper catalyzes the oxidation of organic acids, continuously generating nitrites from nitric acid, thereby maintaining stable nitrite concentration over time despite storage conditions.
Solution Approach 2:
The composition is designed to be self-regulating through the copper-catalyzed oxidation reaction. The system automatically maintains nitrite concentration by using the organic acids as sacrificial reducing agents that continuously react with nitric acid in the presence of copper, without requiring external intervention or hermetic sealing.
2Object-affected harmful factors
If nitric acid concentration is reduced to improve safety, then risk of side effects decreases, but therapeutic effectiveness is compromised
Solution Approach 1:
The patent optimizes the nitric acid concentration to a specific range (5-15 mmol/ml) that balances safety and effectiveness. This intermediate concentration, combined with the copper-organic acid system, provides sufficient therapeutic action while reducing the caustic effects on healthy tissue compared to conventional higher concentrations.
Solution Approach 2:
The patent creates a composite pharmaceutical composition combining nitric acid with copper salts and multiple organic acids. This composite system provides synergistic effects where the copper-organic acid reaction continuously generates nitrites that enhance therapeutic effectiveness at lower nitric acid concentrations, while the buffer capacity of the organic acids mitigates harmful caustic effects.
3Reliability
If multiple active substances are added to improve stability and effectiveness, then therapeutic performance improves, but device complexity increases
Solution Approach 1:
The patent combines multiple functional components (nitric acid, copper salts, lactic acid, oxalic acid, acetic acid) into a single integrated pharmaceutical composition. All components work synergistically within one solution, eliminating the need for separate applications or complex delivery systems, thereby managing complexity while achieving improved therapeutic performance and stability.
4Ease of manufacture
If hermetic sealing is avoided to simplify storage, then ease of manufacture improves, but product stability deteriorates
Solution Approach 1:
The composition is designed to be inherently stable without hermetic sealing by incorporating copper-catalyzed oxidation of organic acids that continuously regenerates nitrites. The system self-maintains its chemical balance through the sacrificial oxidation of organic acids, making hermetic sealing unnecessary and simplifying both manufacturing and storage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves improved stability and effectiveness in treating skin diseases with reduced side effects, enhancing cellular immune response and promoting optimal healing with minimal risk of hyperpigmentation or tissue damage.
Implementation Method 1
copper, together with nitric acid and nitrites, denatures the proteins of the skin, allowing mummification of lesions or diseases of the skin (necrosis of the area containing the lesion)
Implementation Method 2
Zinc has an action on cellular immunity and therefore promotes the fight against infections, particularly in the cells of the human body and therefore also those of the skin
Implementation Method 3
zinc also has a key role in cell membranes and plays an important structural role, enhancing the mediating effect of the cellular immune response
Implementation Method 4
Oxidation of organic acids promotes the reduction of nitric acid by promoting the formation of nitrate reduction products such as nitrous gases and nitrous acid
Data Source
AI summary
Pharmaceutical composition for the treatment of skin diseases, comprises nitric acid aqueous solution (5-15 mmol/ml), a zinc salt (0.01-0.015 mg zinc ion/ml of the composition) and a copper salt (0.01-0.015 mg copper ion/ml of the composition). Independent claims are included for: (1) a process for the preparation of the composition for the treatment of skin diseases comprising adding zinc metal (0.01-0.015 mg zinc ion/ml) at a predetermined quantity of concentrated nitric acid, stirring the predetermined quantity of nitric acid containing zinc till it dissolves, clearing gaseous hydrogen with a reduction of nitric acid into nitrous acid and forming a first solution, adding a copper, preferably in the form of copper nitrate (0.01-0.015 mg Cu 2> +>ions/ ml), and diluting with water; and (2) a medical device comprising an applicator and an ampoule comprising the composition. ACTIVITY : Dermatological; Keratolytic; Virucide; Gynecological; Antiinflammatory; Antiseborrheic; Antipsoriatic; Fungicide; Antibacterial. MECHANISM OF ACTION : None given.